Cowslip

Primula veris L. belongs to Primulaceae, the primrose family, and was published by Linnaeus in Species Plantarum in 1753. Kew’s Plants of the World Online (POWO) accepts the name and gives a native range from Europe to Siberia and Iran; the species is listed as extinct in Algeria. Older literature calls it Primula officinalis, which EMA’s assessors treat as the same plant. Brys and Jacquemyn’s Biological Flora account (Journal of Ecology 2009) recognizes four subspecies, the widespread subsp. veris plus subsp. columnae, canescens, and macrocalyx; one cowslip saponin, primacrosaponin, was first isolated from subsp. macrocalyx. EMA covers P. veris and the oxlip, Primula elatior (L.) Hill, interchangeably, and the European Pharmacopoeia defines primula root as the dried rhizome and root of either species. Linnaeus considered primrose, cowslip, and oxlip varieties of a single species (Grieve), and they still hybridize. Cowslip crossed with the common primrose, P. vulgaris, gives the false oxlip, P. × polyantha, frequent where the parents grow together, while the cowslip–oxlip hybrid, P. × media, is rarely reported in Britain. Evening primrose belongs to a different family, Onagraceae, and shares only part of a common name.

Cowslip is a perennial rosette plant that grows from a short, stout rhizome with a mass of fibrous roots; these underground parts are what is dug for primula root. Brys and Jacquemyn describe wrinkled (rugose) leaves usually 5–15 cm long, occasionally up to 20 cm. From early April to mid-May, peaking at the end of April, one or two flowering stalks, usually 10–20 cm tall, rise from the rosette, each topped by an umbel of 1 to 30 fragrant flowers. Each flower sits in a pale green, five-angled calyx 8–17 mm long, which Grieve likened to a crinkled bag, and the bright yellow corolla opens into a limb 10–17 mm across with an orange mark at the base of each petal, the “rubies” of Shakespeare’s fairies. Cowslip is distylous: some plants (pins) have a long style and low anthers and others (thrums) the reverse, an arrangement Charles Darwin described in 1862. Brys and Jacquemyn call it an obligate outbreeder that depends on insects drawn by its copious nectar, especially long-tongued bumblebees such as Bombus hortorum and Anthophora flower bees. The seeds, 1–1.5 mm long, are shaken out of the capsule censer-fashion and mostly land only a few centimeters from the parent.

Cowslip is a plant of open, herb-rich grassland on calcareous soils, chalk and limestone meadows and pastures above all, and it also grows on woodland edges, cliffs, dunes, and railway banks. It tolerates little shade and is the most drought-tolerant of the three British primulas (Brys and Jacquemyn). Its fortunes have followed farming. The New Atlas of the British and Irish Flora recorded it in 1,413 ten-kilometer squares after 1987, against 1,638 before 1969, a decline of 13.7%, which Brys and Jacquemyn attribute to the ploughing of old grassland, fertilizer use, and the end of traditional hay-meadow management and grazing. From the 1980s it increased again in many parts of the UK because cowslip seed went into wildflower mixtures sown on new road verges, and it showed no further decline from 1986 to 2004. On the Continent, fragmentation and nutrient run-off from surrounding land continue to squeeze small populations. The IUCN European Red List of Medicinal Plants (2014) assesses both cowslip and oxlip as Least Concern, while Germany’s Federal Species Protection Ordinance lists all wild populations of European Primula species as specially protected.

Cowslip’s names describe a meadow flower woven into everyday life. Brys and Jacquemyn report the usual explanation that cowslip is a politer form of cowslop, from the belief that the plant sprang up where cows had dunged, while Maud Grieve’s A Modern Herbal (1931) suggested “cow’s leek,” from the Anglo-Saxon leac, a plant. The drooping flower heads looked like a bunch of keys, so old herbals called it Herb Peter and Key Flower after St Peter’s keys. Grieve traced the idea to Norse lore dedicating the flower to Freya and to its later rededication to the Virgin Mary as Our Lady’s Keys and Key of Heaven; other country names include paigle, palsywort, fairy cups, and petty mulleins. Shakespeare used the flower three times: the fairies’ “cowslips tall” with gold coats and ruby “spots” in A Midsummer Night’s Dream, Ariel lying “in a cowslip’s bell” in The Tempest, and a mole “cinque-spotted, like the crimson drops / I’ the bottom of a cowslip” in Cymbeline. Grieve describes children hanging 50 to 60 flower heads over a string and tying them into cowslip balls, or tosties, and country households brewing cowslip wine from the yellow ‘peeps,’ the petal rings, with sugar, lemon rind, and yeast, then aging it for eight or nine months.

Herbalists prized cowslip mostly for the head and nerves. John Gerard (1597), according to Brys and Jacquemyn, grouped cowslip and primrose as ‘Petty Mulleins’ with similar virtues, recommended the flowers and leaves boiled in wine for diseases of the lungs, and had the juice of the root snuffed up the nose for migraine. Grieve quotes William Turner scolding women who distilled cowslip flowers in white wine to wash away wrinkles, and Nicholas Culpeper praising an ointment of the flowers for spots, wrinkles, sunburn, and freckles while claiming the plant remedied vertigo, palsies, convulsions, and cramps, and that the roots eased pains in the back and bladder. The names palsywort and the Greek Paralysio reflect that reputation. Grieve also cites John Hill (1755) on country people taking powdered root boiled in ale for giddiness and wakefulness, and Hartman’s Family Physitian (1696) claiming that a glass of cowslip wine at bedtime “causes sleep and rest.” By 1931 Grieve listed the flowers as sedative and antispasmodic, used only the yellow corolla plucked from its green calyx, and noted that young leaves were once eaten in salads. Madaus (1938), cited by EMA, added rheumatism, gout, migraine, and nervous headache.

The root’s career as a cough medicine is surprisingly recent. EMA’s assessors trace it to the years after the First World War, when primula root was introduced into European phytotherapy as a substitute for senega root. Flower preparations appear in German sources from 1911 and in the British Herbal Pharmacopoeia (1974), which gave a 1:1 liquid extract. The Austrian Pharmacopoeia has specified primula root extracts since at least 1960, standardizing them by their hemolytic index, a measure of how strongly saponins burst red blood cells. Germany’s Commission E approved both root and flower for catarrh of the respiratory tract, and fixed thyme–primula combinations have been on the EU market since at least 1976. EMA’s herbal committee adopted monographs on primula root and primula flower in 2007 and revised both in September 2012, keeping them as traditional expectorants. A separate thyme–primula combination monograph was first adopted in 2012 and revised in April 2016, granting well-established use to three adult combinations. In September 2025, periodic reviews of the root and flower monographs found no new data that required a revision. In the United States, a 1997 botanical safety classification by McGuffin and colleagues, cited by EMA, placed root and flower in Class 1, herbs that can be safely consumed when used appropriately.

Saponins are the center of the story. EMA’s assessment report puts triterpene saponins at usually 3–10%, occasionally 12%, of the dried root, and Müller, Ganzera, and Stuppner (Journal of Chromatography A 2006) measured up to 14.9% in cowslip roots and found the two species easy to tell apart by their saponin patterns. These are oleanane-type triterpenes with branched sugar chains. In oxlip the main compound is primulasaponin, built on protoprimulagenin A; cowslip’s include priverosaponin B and saponins of anagalligenin and priverogenin B. Apel and colleagues (International Journal of Molecular Sciences 2017) detected primula acid I in the roots, leaves, and petals of cowslip. The root also carries the phenolic glycosides primeverin and primulaverin, up to 2.3%, which on drying release the fragrant compounds responsible for the dried root’s smell; Grieve likened it to anise. The flower is chemically different. EMA says its saponins, up to 2%, sit only in the green sepals, while the petals hold up to 3% flavonoids, including apigenin, rutin, and 3′,4′,5′-trimethoxyflavone, plus carotenoids that give the yellow color. EMA’s figures for the hemolytic index make the contrast concrete: 3,000 for the root, 35 for the flower.

How saponins loosen phlegm is not settled. The explanation repeated in pharmacy texts, and accepted by EMA as plausible rather than proven, is a reflex: saponins irritate the stomach lining, which provokes more watery bronchial secretion and so thins the mucus and makes it easier to cough up. Saponins may also irritate the throat directly, and their detergent-like lowering of surface tension could make sputum less sticky. In cell experiments, alpha-hederin from ivy leaf affects β2-adrenergic receptors, though whether enough reaches the lungs is unclear, and EMA notes that nobody knows whether primula saponins act this way at all. Animal data are thin and old. In rabbits, a primula flower extract increased bronchial secretion about as much as the drugs bromhexine and acetylcysteine (Chibanguza and colleagues 1984), and in a frog throat preparation, dilute root saponins increased ciliary beating while stronger solutions stopped it. In cell culture, primula root extract reduced release of the inflammatory messenger interleukin-8 from human monocytes, more so when combined with thyme, though EMA judged the extracts too poorly described to assess relevance (Nauert and colleagues 2005). Primula extracts and saponins show antifungal, antibacterial, and antiviral effects in laboratory tests, and a root extract inhibited the COX-1 and COX-2 enzymes by 54% and 66%; EMA says none of these effects has been verified in people.

Whether anything reaches the airways is unknown. EMA found no pharmacokinetic data for primula saponins; saponins in general are poorly absorbed, and their sugar chains are readily cleaved in the gut. That poor absorption is also why they are relatively harmless by mouth. Injected, they are another matter: a cowslip saponin fraction had a median lethal dose of 24.5 mg/kg injected into the abdomen of mice, primula acid 1.2 mg/kg intravenously in rats, and injected saponins can break down red blood cells and damage the liver and kidneys, figures EMA considers irrelevant to oral use. EMA cites estimates of about 10 mg of saponins a day in an average UK family diet and more than 200 mg for some vegetarians, and, citing Hostettmann and Marston, considers primula saponins to have a favorable benefit-risk ratio. In the thyme–primula tablets, the only compound anyone has measured in people is thymol from the thyme, which remained detectable as thymol sulfate for up to 41 hours after a single dose (Kohlert and colleagues, cited by EMA). Tests on reproductive toxicity, genotoxicity, and cancer have not been done, which is why EMA has not placed primula on its formal EU list of traditional herbal substances.

Cough with a cold is the only indication EMA accepts for cowslip on its own. Both monographs use the same words: a traditional herbal medicinal product used as an expectorant in cough associated with cold, exclusively based upon long-standing use. Most primula root preparations are for adolescents over 12 and adults, three specific liquids may be used from age 4, and primula flower products are limited to 12 and over. EMA’s assessors found no published clinical trial of primula root or primula flower as the only active ingredient and described the evidence as level 4, plausible from long use and pharmacology. They deliberately left the combination trials out of that assessment, because a combination’s effect cannot be attributed to one ingredient. The 2025 periodic reviews searched PubMed from September 2012 to May 2025 and found 83 new references for each plant part, mostly about other Primula species, combinations, or chemistry, none of which justified a revision. In EMA’s 2012 market survey, root products in Austria, the Czech Republic, Latvia, Poland, and the United Kingdom were combinations only, as were flower products in Austria, the Czech Republic, Estonia, and Germany.

The clinical data come from thyme–primula root combinations, a German tradition. Gruenwald, Graubaum, and Busch (Arzneimittelforschung 2005) randomized 150 adults with acute bronchitis of under 48 hours to thyme–primula drops (Bronchicum Tropfen, 1 ml five times daily) or placebo for 7–9 days. The bronchitis severity score fell from 12.0 to 1.0 points with the drops and from 11.7 to 6.5 with placebo, and 58.7% versus 5.3% were symptom-free at the end. A follow-up single-blind trial in 189 adults found a second thyme–primula liquid as effective as the drops, but it had no placebo group (Gruenwald and colleagues 2006). Kemmerich (Arzneimittelforschung 2007) gave 361 adults Bronchipret TP tablets, 160 mg dry thyme extract and 60 mg dry primula root extract three times daily (n=183), or placebo (n=178) for 11 days. Daytime coughing fits fell 67.1% versus 51.3% by days 7–9, a 50% reduction came about two days sooner, and investigators rated 92.9% versus 75.8% as responders at the end. EMA calculates that the daily dose corresponds to about 1.17 g of primula root. Wagner, Cramer, and colleagues (Forschende Komplementärmedizin 2015) grouped four randomized trials of ivy, primrose, and thyme preparations and found a cough response about 40% more likely than with placebo (risk ratio 1.40).

EMA’s herbal committee judged these three trials good enough to grant well-established use, the stronger of its two categories, to the three tested fixed combinations as expectorants for productive cough in adults; children and adolescents were not in the controlled trials, so those products are not recommended under 18. The committee read “acute bronchitis” in the German trials as a common cold with productive cough. It also recorded that guidance is split: a Cochrane review of over-the-counter cough medicines, the German general-practice guideline, and the American College of Chest Physicians found insufficient evidence for expectorants in acute cough, while the German Respiratory Society’s 2010 guideline strongly recommended thyme with primula. Several caveats apply. Each trial tested one branded product with its own extracts and ratios. Placebo groups improved substantially, as acute coughs do. The effect cannot be split between thyme and cowslip, which is why the thyme monograph on this site cites the same trials. A large post-marketing study of 7,783 patients (Ernst and colleagues 1997) favored the thyme–primula tablet over ambroxol and acetylcysteine, but it was neither randomized nor placebo-controlled, so EMA used it mainly as safety data.

Primula flower’s best-known modern use is in BNO 1016, the dry extract in Sinupret extract tablets made by Bionorica. It combines gentian root, primula flower, sorrel herb, elder flower, and verbena herb in a 1:3:3:3:3 ratio, so cowslip flower makes up three of thirteen parts. Jund and colleagues (Acta Oto-Laryngologica 2015) pooled two placebo-controlled trials in 589 adults with acute viral rhinosinusitis who took 160 mg three times daily or placebo for 15 days. The investigator-rated major symptom score fell from 10.02 to 2.47 points with BNO 1016 and from 9.87 to 3.63 with placebo, a difference of 1.16 points at the end, and patient-rated quality of life was also better. No serious adverse events were reported. Bionorica funded the trials, and one author was a company employee. These are results for the five-herb product at that dose, not for cowslip; EMA’s assessors declined to use the Sinupret data in the primula flower assessment because the flower’s share of the effect cannot be estimated. An older, lower-dose product, BNO 101, has the same five ingredients.

Everything else is folklore or laboratory work. EMA records traditional flower uses for nervousness, headache, sweating out fevers, rheumatism, gout, and as a diuretic, and root uses for rheumatic complaints and migraine and, applied externally, for bruises, but concluded that the flower’s other constituents do not support these indications. Cowslip wine and flower syrups were taken for sleep and giddiness, yet in the only modern behavioral test EMA found, a chick separation-stress model (Sufka and colleagues 2001), cowslip showed no sedative or anti-stress effect, and no human trial has tested it for sleep, anxiety, or headache. Primula saponins inhibit fungi in dishes, and an uncontrolled report of more than 100 people with antibiotic-resistant oral thrush treated with a topical solution of saponins from the related common primrose described lesions clearing within two to three days, but EMA questioned it for lack of controls. None of this supports using cowslip for infections, which need a proper diagnosis.

Primula root, per EMA’s 2012 monograph for adolescents over 12, adults, and the elderly: herbal tea, 0.2–0.5 g of cut root in 150 ml of boiling water three times daily; dry extract (Austrian Pharmacopoeia, drug-extract ratio 3–3.5:1), 0.1–0.2 g three times daily; liquid extract 1:1 in 70% ethanol, 0.5 g three times daily; liquid extract 1:2–2.5 in 70% ethanol, 0.6 g four times daily; tincture 1:5 in 70% ethanol, 0.5–1 g three times daily; and other extracts equivalent to 0.2–0.5 g of root three times daily. Three preparations may be used from age 4: the 1:2–2.5 liquid extract at 0.33 g three times daily, the tincture at 0.3–0.5 ml three times daily, and an ethanolic soft extract at 0.12 g three times daily (four times from age 6). All others are not recommended under 12. For the tea, EMA’s assessors cite Wichtl’s method of putting the root in cold water, bringing it to the boil, and waiting five minutes before straining. If symptoms persist for more than a week, EMA says to see a doctor or qualified practitioner.

Primula flower, per EMA’s 2012 monograph for ages 12 and up: herbal tea, 1 g of cut flowers in 150 ml of boiling water three times daily, or a 1:1 liquid extract in 25% ethanol, 1–3 ml up to three times daily, with a maximum of 6 ml a day. Because the saponins sit only in the sepals, EMA’s assessors say the complete flowers, calyx included, must be used for cough; the yellow petals alone, which Grieve recommended and which go into cowslip wine, lack them. For the thyme–primula combinations, EMA’s well-established adult doses are 160 mg dry thyme extract with 60 mg dry primula root extract three times daily (the Kemmerich tablet), 0.43 g liquid thyme extract with 0.21 g primula root tincture five times daily (the Gruenwald drops), and 0.5 g liquid thyme extract with 0.25 g liquid primula root extract six times daily; none is recommended under 18. Other combinations sit on the traditional shelf, three of them from age 4, for example 0.36 g liquid thyme extract with 0.18 g primula root tincture three to five times daily for children aged 4–11.

Practical points: read the label for Primula veris or Primula elatior and for root (radix) or flower (flos), because the two are separate products with separate age limits, and do not confuse primula with evening primrose oil capsules. Many tinctures and liquid extracts contain ethanol, and EMA’s assessors did not recommend one ethanol-containing thyme–primula liquid for children under 2, even though its alcohol content was very low. Primula flower has no European Pharmacopoeia monograph, while primula root does, so flower quality is set by national standards such as the German Drug Codex. Do not dig wild cowslips for their roots: populations are patchy, and in Germany wild plants are legally protected. Cowslip wine is an alcoholic country drink, not a medicine, and Grieve’s recipe used a gallon of petal rings with 4 pounds of sugar, so its traditional reputation as a sleep aid says little about the plant. If a cough is accompanied by breathlessness, fever, or pus-like phlegm, EMA says to stop self-treating and see a clinician.